Wuhan YZY Biopharma Co., Ltd. (02496.HK)

Wuhan YZY Biopharma Co., Ltd. engages in the research, development, and industrialization of bispecific drugs. The company is headquartered in Wuhan, Hubei and currently employs 106 full-time employees. The company went IPO on 2023-09-25. The firm is committed to developing bispecific antibody (BsAb) based therapies for the treatment of cancer-related complications, cancer, and age-related eye diseases to address the medical needs in oncology and geriatric eye diseases. The firm's core product M701 is a recombinant BsAb that targets human cancer cell surface antigen EpCAM and human T cell surface antigen CD3. The firm's product pipeline also includes Y101D, Y332, Y225, and others.